Avvinity Therapeutics was founded in 2016 as an immuno-oncology joint venture between Horizon Discovery and Centauri Therapeutics.  The new company combined Horizon’s gene editing, immunology, oncology and drug discovery expertise with Centauri’s Alphamer technology to launch a proprietary platform for the discovery and development of immuno-oncology therapeutics for solid tumours, leukaemia and lymphomas. Today, with support from LifeArc and the UK Government’s Future Fund, the company operates independently from its founders however the Avvinity team continues to strive to meet these goals.

Avvinity Group Photo

Avvinity’s founding team

Avvinity’s Future

The Avvinity team, with support from its external scientific advisors and collaborators, is using investment from LifeArc and the UK Government’s Future Fund, to take new compounds into pre-clinical studies. The flexibility of the technology makes it amenable to partnering with other compounds for products to treat alternative disease areas and the team are keen to explore such opportunities with potential collaborators.  Please get in touch using our contact details if you would like to discuss this further.

“Science consistently produces a new crop of miraculous truths and dazzling devices every year.”

Kary Mullis, Nobel Laureate (1944-2019)